The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Female patients aged ≥ 18 years.
Histologically confirmed HER2-positive breast cancer (IHC 3+ or IHC 2+ with ISH+).
Patients expected to receive pyrotinib-containing regimens for neoadjuvant therapy or metastatic/unresectable breast cancer.
·≤1 prior line of anti-HER2 therapy during the recurrent/metastatic stage.
Ability to operate a mobile phone and read independently.
Deemed psychologically and physically suitable for participation by the investigator.
You may not be if
History of cognitive impairment.
Severe visual or auditory impairments.
Prior use of pyrotinib.
Pregnancy, lactation, or intention to conceive.
Ineffective cognitive-behavioral interventions within the past year.
Participation in other clinical trials within 1 month prior to screening.
Investigator judgment of unsuitability due to psychological or physical conditions.
Clareo Health | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study
